Two Doses of 3TC (Lamivudine; GR109714X) for Patients 12 Years and Older

This study focuses on a medication called 3TC, or Lamivudine, for individuals aged 12 and above. The main goal is to evaluate the effectiveness of two different doses of 3TC, with the duration of treatment decided by the patient's doctor or until the program ends. For those under 12, a lower dose of 3TC is provided. The study is particularly important as it aims to improve treatment options for the condition, offering valuable insights into the use of 3TC. During the study, participants are monitored monthly. In some selected locations, blood samples are collected every three months from patients who test positive for HBsAg. An amendment made on 02/28/95 allows patients enrolled before 03/01/95 to either continue with their current dose of 3TC or switch to a combination therapy involving 3TC and another medication, zidovudine.